The American vaccine development company, Novavax, said that the US Food and Drug Administration has granted expanded authorization for the emergency use of its anti-Covid-19 vaccine, which includes an ingredient to strengthen the response, in adolescents aged 12 to 17 years.
The American company said that the vaccine is the first protein-based Covid-19 vaccine authorized in the United States.
The company indicated that doses of the vaccine are available for use with adolescents, based on the recommendation of the Centers for Disease Control and Prevention.
In July 2022, the FDA granted emergency use authorization for an initial two-dose series in adults over 18 years of age, followed by a recommendation from the CDC’s Advisory Committee on Immunization Practices, and endorsement by the CDC.
#America #approves #vaccine #teenagers #Corona